{"url_path":"/sec/indv/8-k/2026-05-15/item-5-07","section_key":"item-5-07","section_title":"Item 5.07 Submission of Matters to a Vote of Security Holders.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-15","source_url":"https://www.sec.gov/Archives/edgar/data/1625297/0001625297-26-000024-index.html","accession_number":"0001625297-26-000024","cik":"0001625297","ticker":"INDV","issuer_name":"Indivior Pharmaceuticals, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1625297/0001625297-26-000024-index.html","primary_entity_key":"0001625297","primary_entity_name":"Indivior Pharmaceuticals, Inc."},"word_count":384,"has_tables":true,"body_markdown":"Item 5.07 Submission of Matters to a Vote of Security Holders.\n\nThe Company held a virtual annual meeting of stockholders on May 13, 2026, at 10:00 a.m. Eastern Time. A total of 121,922,058 shares of common stock of the Company were entitled to vote as of March 18, 2026, the record date for the Annual Meeting, of which 100,407,7225 were present in person or by proxy at the Annual Meeting. Details of each matter voted upon were described in a definitive proxy statement filed with the U.S. Securities and Exchange Commission on March 27, 2026 (the \"Proxy Statement\"). The stockholders duly elected each person nominated to serve as a director, and approved each matter presented, by the following votes:\n\n1.To elect eight director nominees, each to serve for a one-year term extending until our 2027 Annual Meeting of Shareholders and until their successors are duly elected and qualified:\n\nNomineeVotes ForVotes AgainstVotes AbstainedBroker Non-Votes\n\nDr. David Wheadon91,378,8281,534,06424,8047,470,026\n\nJoe Ciaffoni92,834,81176,83926,0467,470,026\n\nDr. Keith Humphreys92,839,95572,08425,6577,470,026\n\nTony Kingsley92,839,46972,50325,7247,470,026\n\nDaniel Ninivaggi87,545,0325,366,84925,8157,470,026\n\nBarbara Ryan91,562,1951,302,38373,1187,470,026\n\nMark Stejbach92,838,96272,84725,8877,470,026\n\nJuliet Thompson92,136,342728,04073,3147,470,026\n\n2. To approve, on an advisory basis, the compensation of our named executive officers as disclosed in the Proxy Statement (Say-on-Pay):\n\nVotes ForVotes AgainstVotes AbstainedBroker Non-Votes\n\n90,364,5661,324,9961,248,1347,470,026\n\n3. To indicate, on an advisory basis, the preferred frequency of shareholder advisory votes on the compensation of our named executive officers (Say-on-Frequency):\n\nVotes For 1 YearVotes For 2 YearsVotes For 3 YearsVotes AbstainedBroker Non-Votes\n\n91,848,95421,7011,032,94134,1007,470,026\n\nIn light of the shareholder vote, and in keeping with the Board’s recommendation on Proposal 3, the Company will hold a “say-on-pay” vote annually until the next vote on the frequency of “say-on-pay” votes is required (which will be no later than the 2032 Annual Meeting of Shareholders) or until the Board determines that a different frequency for “say-on-pay” votes is in the best interest of the Corporation and its shareholders.\n\n4. To ratify the appointment of PricewaterhouseCoopers LLP US (PwC) as our independent registered public accounting firm for the fiscal year ending December 31, 2026:\n\nVotes ForVotes AgainstVotes AbstainedBroker Non-Votes\n\n99,146,2411,237,98423,4970\n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\nIndivior Pharmaceuticals, Inc.\n\nDate: May 15, 2026\nBy:/s/ Ryan Preblick\n\nName: Ryan Preblick\n\nTitle: Chief Financial Officer"}